Clinical trials: Genital Neoplasms
Prostatic Neoplasms, Castration-Resistant
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety and tolerability of JNJ-56021927 in Japanese participants with metastatic castration-resistant prostate cancer (mCRPC- prostate cancer that is resistant to medical [for example.
- Trial name
- NCT02162836
- Testing
- JNJ-56021927
- Where
- 4 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Janssen Pharmaceutical K.K.
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Prostate Cancer
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
The study was a three-arm, active-control, multi-centre, parallel group study.
- Trial name
- NCT00295750
- Testing
- Degarelix, Leuprolide 7.5 mg
- Where
- 35 sites in United States, Canada and 10 more
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
External Anogenital Warts
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents
The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in the treatment of external anogenital warts in children and adolescents.
- Trial name
- NCT01111344
- Testing
- Glizigen + Viusid
- Where
- Cuba
- Volunteers
- 76 people
- Sponsor
- Catalysis SL
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.
- Trial name
- NCT00002445
- Testing
- IM862
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 200 people
- Sponsor
- Cytran
Genital Neoplasms, Female
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
- Trial name
- NCT02182245
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Malnutrition; Protein, Cancer, Lung
Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients
The goal of this clinical trial is to evaluate the efficacy oral nutrition supplement (ONS) in malnutrition/high risk malnutrition cancer patients. The main questions it aims to answer: 1.
- Conditions
- Malnutrition; Protein, Cancer, Lung, Cancer Cervix
- Trial name
- NCT06128694
- Testing
- NUTRICAN
- Where
- Indonesia
- Volunteers
- 108 people
- Sponsor
- Kalbe International Pte. Ltd
PIK3CA Mutations, Advanced Solid Tumors, Adult
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of…
- Conditions
- PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
- Trial name
- NCT07383506
- Testing
- CGT6297
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cogent Biosciences, Inc.
Ovarian Neoplasms
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive…
- Trial name
- ICEBERG 3 (NCT00628251)
- Testing
- AZD2281, Liposomal Doxorubicin
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 97 people
- Sponsor
- AstraZeneca
Prostate Cancer
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer…
- Trial name
- NCT00659438
- Testing
- ZD6474 (Vandetanib), Bicalutamide
- Where
- 5 sites in France
- Volunteers
- 95 people
- Sponsor
- Genzyme, a Sanofi Company
Human Papilloma Virus, Human Papilloma Virus Infection
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR.
- Conditions
- Human Papilloma Virus, Human Papilloma Virus Infection, Cervix Lesion
- Trial name
- PALOMA2 (NCT04199078)
- Testing
- Papilocare vaginal gel
- Where
- 19 sites in Spain
- Volunteers
- 164 people
- Sponsor
- Procare Health Iberia S.L.
Cervical Neoplasms, Human Papillomavirus
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
The purpose of the study is to assess the cumulative disease detection of greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) and greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) in the…
- Trial name
- NCT02267876
- Testing
- BD HPV Assay on Viper LT, Colposcopy
- Where
- 40 sites in United States, Canada
- Volunteers
- 6,730 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002138
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Ovarian Cancer
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
- Trial name
- NCT05475184
- Testing
- JPI-547
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Onconic Therapeutics Inc.
Prostate Cancer
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486 CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix).
- Trial name
- NCT00117949
- Testing
- Degarelix
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety, tolerability and pharmacokinetics of ODM-204 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- DUALIDES (NCT02344017)
- Testing
- ODM-204, Prednisone
- Where
- 4 sites in Finland, France and 2 more
- Volunteers
- 23 people
- Sponsor
- Orion Corporation, Orion Pharma
Cervical Cancer
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer
- Trial name
- NCT03444376
- Testing
- GX-188E, KEYTRUDA®
- Where
- 9 sites in South Korea
- Volunteers
- 65 people
- Sponsor
- Genexine, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.